Budesonide Inhalant
Product Images NDC 68788-7314

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 68788-7314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 00

Budesonide Inhalation Suspension 0.5mg/2mL label showing it as a generic for Pulmicort. The label includes dosage form (inhalant), package size details, and manufacturer Cipla USA, Inc. Warnings and storage instructions are provided. The label is bilingual in English and Spanish, with usage directions and a barcode.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 01

Chemical structure diagram of Budesonide, showing its molecular arrangement with carbon rings, hydroxyl groups, and ester functional groups.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 02

A line chart depicting the mean change from baseline in nighttime asthma symptoms over a 12-week period. The x-axis represents time from baseline to week 12, and the y-axis shows the mean change in symptoms. Four lines represent placebo, 0.25 mg, 0.5 mg, and 1.0 mg once-daily doses of Budesonide inhalation suspension.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 03

A line graph depicting mean change from baseline in nighttime asthma symptoms over a 12-week period. The x-axis represents time intervals from baseline to weeks 0-12, and the y-axis shows the mean change values. Three lines illustrate different dosage groups: 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg twice daily, showing trends in symptom changes over time.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 04

A line graph showing mean change from baseline in nighttime asthma symptoms over 12 weeks. The x-axis represents time intervals from baseline to week 10-12, and the y-axis shows mean change values. Lines represent different treatments: placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily, each indicated by distinct markers.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 05

An instructional illustration showing a hand removing the cap from a small vial or ampule, with an arrow indicating the direction to turn or pull the cap. This is step number 2 in a sequence, likely related to preparing Budesonide Inhalation Suspension for use.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 06

An instructional black-and-white illustration showing hands twisting the top off a small plastic single-dose vial, presumably for inhalation suspension. The image indicates the correct method of opening the vial by twisting the cap.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 07

An instructional illustration showing a hand shaking or preparing a Budesonide Inhalation Suspension device. The image, marked with the number 4 in the corner, depicts a user handling the inhaler apparatus, indicating preparation or activation steps for proper medication delivery.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 2

An instructional illustration showing a hand holding an ampule while opening a sealed pouch. The ampule is partially withdrawn from the pouch, demonstrating the initial step in preparing the medication for use.*

FDA Label Image

87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 3

Instructional illustration showing a person's hands opening an ampule from a strip of four ampules, likely related to a liquid inhalation suspension. The image demonstrates how to separate and access a single dose ampule for use, corresponding to Budesonide Inhalation Suspension.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.